The effectiveness of mebicar in chronic coronary heart disease | Zendy

R. A. Kamburg | Zendy; D. A. Valimukhametova | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The effectiveness of mebicar in chronic coronary heart disease

Author(s) -

R. A. Kamburg,

D. A. Valimukhametova

Publication year - 1984

Publication title -

kazan medical journal

Language(s) - English

Resource type - Journals

eISSN - 2587-9359

pISSN - 0368-4814

DOI - 10.17816/kazmj89505

Subject(s) - medicine , coronary heart disease , bradycardia , pharmacotherapy , intensive care medicine , circulatory system , cardiology , heart disease , disease , chronic disease , coronary disease , heart rate , blood pressure

Modern pharmacotherapy of chronic coronary heart disease (HIBS) is based on the use of two main groups of drugs nitrates and beta-blockers. The effectiveness of other drugs in the complex treatment of this disease is being reviewed and constantly debated [1, 2]. The treatment of HIBS, combined with bradycardia, circulatory insufficiency, bronchospastic conditions, intolerance or contraindications to the use of nitrates and beta-blockers, is a great difficulty.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research